source
- FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancersThe U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
- Isomorphic Labs raises record $5 billion in Series C, doubling its May fundingIsomorphic Labs, an AI-driven drug design company, announced a $5 billion Series C financing, the largest private biotech raise ever and more than double its $2.1 billion Series B from May. The ro…